GO
Loading...

GlaxoSmithKline PLC

More

  • Glaxo's Avandia Raises Heart Disease Risk: Study Monday, 21 May 2007 | 5:29 PM ET

    GlaxoSmithKline's widely prescribed diabetes drug Avandia is linked to a greater risk of heart attack and possibly death, a new scientific analysis revealed, and the U.S. government issued a safety alert.

  • Stop Trading! Monday, 21 May 2007 | 4:04 PM ET

    On Stop Trading! today, Cramer reiterated his bullish stance on the oil drillers. Also, when it comes to tech -- look out below.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Hot Stocks: Elan, Williams Among Big Movers Monday, 21 May 2007 | 1:28 PM ET

    M&A news and drug trial updates provided some of the catalysts behind the most actively traded stocks on Monday.

  • 'Slingers' All Around! Friday, 18 May 2007 | 12:45 PM ET

    It sits there in front of you: a plate filled to the overflow point with chili -- and under it, two cheeseburger patties, fried potatoes and one egg, over easy.What are you about to do?

  • Medical Journal Raises Questions About Merck Vaccine Wednesday, 9 May 2007 | 6:07 PM ET

    The New England Journal of Medicine said in an editorial Wednesday that Merck's Gardasil, a treatment for human papillomavirus or HPV, appears to be safe and effective but "a cautious approach may be warranted" due to unanswered questions about the drug's long-term effectiveness and potential for adverse effects that could emerge over time.

  • Alli: Buy the Book Wednesday, 2 May 2007 | 11:47 AM ET

    GlaxoSmithKline's Alli (pronounced "ally" -- don't ask me why they put an "i" at the end) is the new over-the-counter version of prescription Xenical from Roche. It's a diet pill, but as I previously blogged, it has potentially embarrassing side effects. On the plus side, GSK says you can subtract 50% more pounds if you use Alli as directed. But, if you still eat too many fatty foods, you could run into trouble.

  • Glaxo Wins FDA Approval for Allergy Spray Friday, 27 Apr 2007 | 5:44 PM ET

    Analysts have projected peak sales of up to $1 billion a year for the allergy treatment, which is chemically known as fluticasone furoate.

  • Tamiflu Turnaround Thursday, 26 Apr 2007 | 11:35 AM ET

    Is this a sign that the world has become complacent about the pandemic flu threat? Or that some people think it was all a bunch of hooey?Roche today is announcing that it's cutting back production of Tamiflu. When bird flu stories and fears started reaching critical mass more than a year ago, Roche came under considerable criticism for not being able to make enough Tamiflu to meet the sudden spike in demand.

  • Glaxo First-Quarter Profits Down 1%, Hit by Strong Pound Wednesday, 25 Apr 2007 | 9:52 AM ET

    GlaxoSmithKline profits dipped 1% in the first quarter, as sales were hit by the strength of sterling and the loss of patent protection on key medicines, Europe's biggest drugmaker said on Wednesday.

  • Several other major drug companies were apparently interested in buying MedImmune, including Merck, Eli Lilly and possibly Novartis, CNBC’s David Faber reported Tuesday.

  • Controversy? What Controversy? Friday, 20 Apr 2007 | 9:52 AM ET

    Gardasil -- Merck's new vaccine for HPV and cervical cancer -- has been a lightning rod for social controversy since it came to market in the second half of last year. Should Merck be lobbying state's to mandate it? Should parents be forced to have their pre-adolescent, presumably pre-sexually-active kids to get it? Who will pay for it? (It costs about $400 for all three shots which are given over several months.)

  • Glaxo, Merck Maneuver for Position in HPV Drug Market Tuesday, 17 Apr 2007 | 3:41 PM ET

    Merck and GlaxoSmithKline both released news about their respective treatments for human papillomavirus Tuesday, leaving them "duking it out over what's expected to be the multi-billion dollar HPV cervical cancer vaccine market," reported CNBC's Mike Huckman.

  • No. 1 - Big Pharma Buyout Boom Friday, 13 Apr 2007 | 10:54 AM ET

    The maker of the FluMist vaccine said it was putting istself up for sale, causing its shares to surge more than 10%. MedImmune also said that certain major drugmakers had already indicated they might be interested in a takeover.

  • CBS Radio Cancels Don Imus Show, Effective Immediately Thursday, 12 Apr 2007 | 5:02 PM ET
    Radio personality Don Imus appears on Rev.Al Sharpton's radio show, in New York Monday April 9, 2007. Imus issued another apology for referring to the Rutgers women's basketball team as "nappy-headed hos" on his morning show last week. (AP Photo/Richard Drew)

    CBS fired Don Imus from his radio show Thursday, the finale to a stunning fall for one of the nation's most prominent broadcasters.  Imus initially was suspended  for calling the Rutgers women's basketball team "nappy-headed hos" last week, but outrage continued and advertisers bolted from his programs.

  • MedImmune Hires Goldman to Explore Sale Thursday, 12 Apr 2007 | 11:09 AM ET

    U.S. biotechnology company MedImmune  has hired Goldman Sachs to explore a sale of the company, which has a market capitalization of $8.8 billion, people familiar with the situation said on Thursday.

  • Spotlight on Glaxo Heart Drug as Others Fail Thursday, 12 Apr 2007 | 10:24 AM ET

    The failure of rival heart drugs has put the spotlight on a novel GlaxoSmithKline compound that will reach a critical stage of testing this year, after languishing in development for years.

  • MSNBC Drops Don Imus Radio Simulcast Thursday, 12 Apr 2007 | 9:21 AM ET
    Radio personality Don Imus appears on Rev.Al Sharpton's radio show, in New York Monday April 9, 2007. Imus issued another apology for referring to the Rutgers women's basketball team as "nappy-headed hos" on his morning show last week. (AP Photo/Richard Drew)

    NBC News has decided that its cable news channel, MSNBC will no longer simulcast the Don Imus radio program, effective immediately.  CBS Radio says its two week suspension of the program stands although it is monitoring the situation.  Advertisers have been defecting from the controversial radio host.

  • CNBC's Deutsch: "I Think Imus Is Done" Wednesday, 11 Apr 2007 | 3:00 PM ET

    The storm over Don Imus' racial comments escalated as more advertisers pulled out from his show. CNBC's Donny Deutsch told "Power Lunch" that "I think Imus is done."

  • An experimental bowel drug from GlaxoSmithKline and its partner Adolor has little commercial future following safety problems that caused trials to be put on hold, analysts said on Tuesday.

  • It's Time for the Lightning Round! Monday, 9 Apr 2007 | 8:37 PM ET

    It was an extra-long Lightning Round today. So that means Cramer covered everything from retail to tech to banks to agriculture -- and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.